Veropharm, one of Russia's largest drug makers, saw first quarter 2011 net profit increase 180 percent year on year to 338.342 million rubles ($12.11 million) to IFRS, the company said on Thursday.
The company's revenue for the quarter grew by 43.6 percent to 1.383 billion rubles year-on-year.
EBITDA rose 109.1 percent in the first three months of 2011 to 415.5 million rubles, while the EBITDA margin increased to 30 percent from 20.6 percent, Veropharm said in a statement.
Veropharm's debt amounted to 440.9 million rubles in January-March 2011, or less than 20 percent of the company's net assets.
Investment in January-March 2011 plummeted to 11.592 million rubles from 63.186 million rubles in the same quarter of the previous year.
